We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DuPont (DD) to Upgrade Probiotics Facility in Wisconsin
Read MoreHide Full Article
DuPont’s (DD - Free Report) Nutrition & Health segment has announced that it will expand its probiotics pilot facility in Madison, WI. The $10 million investment will further reinforce DuPont’s position as a leading player in the probiotics industry. Further, this will expedite the development of new products and significantly hasten the delivery of pilot materials for clinical trials and customer evaluations.
The Madison probiotics pilot area provides increased capacity and speed for new product development. This in turn helps to improve the overall scale up capability and provides a seamless transition to commercial scale production. Construction of this area has been completed in phases over the last six months.
The new facility features state-of-the-art equipment, data collection, laboratories, instrumentation and specialized work space for probiotic development and scale up. The upgrades have already increased the bandwidth to run more development projects while improving scale up efficiency and time to market.
DuPont has outperformed the industry over the last three months. The company’s shares have moved up 6.9% over this period, compared with the industry’s gain of around 4.7% over the same period.
DuPont kept its positive earnings surprise streak alive with a solid beat in second-quarter 2017. The company recorded adjusted earnings of $1.38 per share in the reported quarter, up 11% from $1.24 per share a year ago. Results topped the Zacks Consensus Estimate of $1.29. DuPont logged net sales of $7,424 million, up roughly 5% year over year on higher volumes. The figure surpassed the Zacks Consensus Estimate of $$7,260 million.
DuPont is well positioned to gain from its cost-cutting and productivity improvement measures and product launches. The company has numerous new products in its pipeline that are expected to create value for customers.
Moreover, the planned mega-merger with Dow Chemical (DOW - Free Report) is expected to deliver cost synergies of around $3 billion and growth synergies of roughly $1 billion. The companies expect the closing of the merger to take place on Aug 31.
E.I. du Pont de Nemours and Company Price and Consensus
BASF has an expected long-term earnings growth of 8.6%.
Chemours has an expected long-term earnings growth of 15.5%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Image: Bigstock
DuPont (DD) to Upgrade Probiotics Facility in Wisconsin
E.I. du Pont de Nemours and Company Price and Consensus | E.I. du Pont de Nemours and Company Quote
Zacks Rank & Stocks to Consider
DuPont currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the chemical space are BASF SE (BASFY - Free Report) and The Chemours Company (CC - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
BASF has an expected long-term earnings growth of 8.6%.
Chemours has an expected long-term earnings growth of 15.5%.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>